Head-to-head evidence
albuterol / budesonide vs Salbutamol HFA-152a
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
Salbutamol HFA-152a
Developed by GlaxoSmithKline
NCT06261957 · Phase 3 · completed
The trial randomized 477 participants and used quadruple blinding with an active salbutamol comparator. Its primary clinical safety endpoint was the number of participants with adverse events, but results are not posted, so whether the primary comparison was favorable cannot be determined.
Next expected readout: February 2027 · NCT06433921 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · Salbutamol HFA-152a's landscape